Drug Profile
Research programme: eye disorder therapeutics - CalciMedica
Alternative Names: GB-201- CalciMedica ; GB-202; GB-203Latest Information Update: 22 Mar 2023
Price :
$50
*
At a glance
- Originator GrayBug inc.
- Developer CalciMedica
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma; Wet age-related macular degeneration
Most Recent Events
- 20 Mar 2023 GrayBug inc. has merged with CalciMedica to form CalciMedica
- 28 Jun 2021 No recent reports of development identified for preclinical development in Glaucoma in USA (Subconjunctival, Injection)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Intravitreous, Controlled release)